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Background: Although several studies have demonstrated early survival advantages with peritoneal dialysis (PD)
over hemodialysis (HD), the reason for the excess mortality observed among incident HD patients remains to be
established, to our knowledge. This study explores the relationship between mortality and dialysis modality,
focusing on the role of HD vascular access type at the time of dialysis initiation.
Methods: A retrospective cohort study was performed among local adult chronic kidney disease patients who
consecutively initiated PD and HD with a tunneled cuffed venous catheter (HD-TCC) or a functional arteriovenous
fistula (HD-AVF) in our institution in the year 2008. A total of 152 patients were included in the final analysis
(HD-AVF, n = 59; HD-TCC, n = 51; PD, n = 42). All cause and dialysis access-related morbidity/mortality were evaluated
at one year. Univariate and multivariate analysis were used to compare the survival of PD patients with those who
initiated HD with an AVF or with a TCC.
Results: Compared with PD patients, both HD-AVF and HD-TCC patients were more likely to be older (p<0.001)
and to have a higher frequency of diabetes mellitus (p= 0.017) and cardiovascular disease (p= 0.020). Overall,
HD-TCC patients were more likely to have clinical visits (p= 0.069), emergency room visits (p<0.001) and hospital
admissions (p<0.001). At the end of follow-up, HD-TCC patients had a higher rate of dialysis access-related
complications (1.53 vs. 0.93 vs. 0.64, per patient-year; p<0.001) and hospitalizations (0.47 vs. 0.07 vs. 0.14, per
patient-year; p= 0.034) than HD-AVF and PD patients, respectively. The survival rates at one year were 96.6%, 74.5%
and 97.6% for HD-AVF, HD-TCC and PD groups, respectively (p<0.001). In multivariate analysis, HD-TCC use at the
time of dialysis initiation was the important factor associated with death (HR 16.128, 95%CI [1.431-181.778],
p= 0.024).
Conclusion: Our results suggest that HD vascular access type at the time of renal replacement therapy initiation is
an important modifier of the relationship between dialysis modality and survival among incident dialysis patients.Background
Early referral of chronic kidney disease (CKD) patients
to nephrology centres may enable patients to be ad-
equately informed regarding the different renal replace-
ment treatment (RRT) modalities [hemodialysis (HD),
peritoneal dialysis (PD) and kidney transplantation* Correspondence: coentrao@med.up.pt
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reproduction in any medium, provided the or(TX)], leading to better results in terms of morbidity
and mortality [1-4]. Large registry-based studies have
suggested a survival advantage of PD over HD, particu-
larly during the first 1 to 2 years of treatment [5,6]. Al-
though the ability of PD to provide better preservation
of residual renal function was invoked as a possible ex-
planation for the survival advantage of PD over HD dur-
ing the first years of treatment, case mix differences in
patients initiating HD may have confounded the inter-
pretation of the studies that examined the influence of
the dialysis modality on patient survival [5-7].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recognized to have a significant influence on survival.
The use of a tunneled cuffed catheter (TCC) is asso-
ciated with a substantially greater risk of sepsis,
hospitalization and mortality compared to the use of an
arteriovenous fistula (AVF) [8-12]. Although technique
survival with PD is shorter than that with HD, in part
due to access-related infections, the frequency of PD
catheter-related complications has decreased in recent
years, with a low rate of bacteremia/sepsis [13,14]. How-
ever, there are few studies comparing the outcomes of
incident PD patients with those of HD patients using
different vascular access types at dialysis initiation in the
literature, to our knowledge [15,16]. In the study pre-
sented here, we hypothesize that vascular access type at
the time of dialysis initiation accounts for the higher
early mortality rate observed in patients who start HD
with a catheter, compared to those who initiate HD with
a functioning fistula or PD. To test our hypothesis, we
compared all-cause and dialysis access-related morbid-
ity/mortality between PD and HD patients with the lat-




We conducted a retrospective observational cohort
study among CKD patients (age 18 years and older at
the start of RRT) who consecutively initiated HD be-
tween January 1 and July 1 2008, or PD between January
1, 2008 and July 1, 2009, in our institution.
The study was approved by the Ethics Committee for
Health and the Local Institutional Review Board of São
João Hospital Centre, Porto, Portugal.
Setting
Portugal has a higher incidence of end stage-renal dis-
ease, ESRD (i.e. the patients who start any RRT modality
for the first time) and prevalence in compared to most
of other European countries. In 2009, an incidence rate
of 240 and a prevalence of 1507 patients per million of
the population were registered in ERA-EDTA [17]. Spe-
cifically, 10,152 patients underwent HD and 660 patients
PD in 2010 (registered by the Portuguese Society of
Nephrology). In Portugal, HD is almost exclusively
(~90%) provided by outpatient hemodialysis units run by
private providers. Hemodialysis patients undergo 4 hours
of dialysis three times weekly, aiming for a spKt/V of 1.4
or greater. Patients undergo treatment using high-flux
dialyzers; no hemodialyzer is reused. Peritoneal dialysis
is provided by public hospitals and university centres.
Patients attending our hospital center undergo either
continuous ambulatory peritoneal dialysis (CAPD) or
automated cyclic peritoneal dialysis (CCPD). All patientshave a 1 to 2 week training period before initiation of
therapy at home. Treatment of PD patients is individua-
lized: the total Kt/V (renal and peritoneal clearance)
aimed for is 1.8 or more and the majority of patients are
treated with dextrose-based solutions with daily ex-
change with Extraneal (Baxter Healthcare Corp, Deer-
field, IL, USA).
Patients
The patients were recruited from the Department of
Nephrology of São João Hospital Centre which is a
tertiary-care University Hospital responsible for nephro-
logical medical support to ESRD patients beginning RRT
within the northwest region of Portugal. Patients were
enrolled if they had a diagnosis of end-stage CKD
according to a nephrologist and had received outpatient
chronic dialysis treatment. Patients who had previously
undergone RRT (HD, PD or TX) and restarted during
the study period and patients transferred to another dis-
trict immediately after starting RRT were excluded. The
RRT modality adopted was based on patient choice and
his/her medical status. Initial dialysis modality was
defined as the modality at the first outpatient dialysis
treatment: patients starting PD therapy assigned to the
PD group and patients starting HD therapy with a tun-
nelled cuffed catheter or a functioning fistula to the HD-
TCC or HD-AVF groups, respectively. Although changes
in vascular access type were recorded during follow-up,
patients remained in the same index group. Follow-up
started on the day dialysis was first performed as an out-
patient and continued for 1 year or until death or
switching from the RRT modality. Because of the rela-
tively lower number of patients who initiated PD be-
tween January 1, 2008 and July 1, 2008 compared to
those who initiated HD, the recruitment period for inci-
dent PD patients was extended to July 2009.
A total of 191 CKD patients started RRT during the
study period (133 HD, 58 PD). Twenty-three HD
patients were excluded from the study due to previous
RRT (n = 13) or loss to follow-up because of transfer to
another district (n =10). In addition, 16 PD patients were
excluded from the study because they had previously
undergone RRT (HD, 11 patients; TX, 5 patients). A
total of 152 patients were included in the final analysis.
Of the 110 incident HD patients, 59 started therapy with
a functioning AVF and 51 with a TCC. Three cohorts of
incident dialysis patients were then established: HD-AVF
(n = 59), HD-CVC (n = 51) and PD (n = 42).
Data
Clinical data and information regarding access type were
collected from our hospital database and from out-
patient dialysis unit records, when appropriate. A phys-
ician assessed the presence of co-morbid illness by
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ment date. Information was collected for the 19 variables
that constitute the Charlson Comorbidity Index [18],
which has been validated for use in patients with ESRD.
The number of clinical and emergency room visits, hos-
pitalizations and dialysis access complications were
determined for all participants from our hospital data-
base and from outpatient dialysis unit records, when
appropriate.
Complications of HD and PD accesses were classified
as mechanical or infectious events [19,20]. Mechanical
complications included AVF stenosis, thrombosis, bleed-
ing and limb ischemia; TCC flow dysfunction, thrombosis,
bleeding, cuff extrusion and complications of central
venous catheterization; PD catheter flow dysfunction,
bleeding, leaks, cuff extrusion, hernias and complications
related to Tenckhoff catheter placement. Infectious com-
plications included AVF-related bacteremia, TCC-related
bacteremia, PD-related peritonitis and bacteremia.
Dates of renal transplantation, switch from the RRT
modality and/or death were known until end off follow-up.
Outcomes
The primary aim of this analysis was to determine the
all-cause mortality of HD-AVF, HD-TCC and PD
patients at 1 year from the time of first dialysis.
A secondary aim was to examine the dialysis access-
related morbidity/mortality of HD-AVF, HD-TCC and
PD patients at 1 year from the time of first dialysis.
Statistical analysis
Data are given as percentages and means ± SD. Cat-
egorical variables were compared using Fisher’s exact
test. The Kruskal-Wallis test was used to analyze differ-
ences between continuous variables. Rates were calcu-
lated for each patient by dividing the number of
events/procedures by the duration of follow-up in
years. Survival on dialysis was calculated by the
Kaplan-Meier method. Univariate analysis of survival
was performed by the log rank method. Multivariate
analysis of survival was performed using a Cox propor-
tional hazards model. Covariates were included if the
baseline difference between the three groups was <0.10.
All tests were two sided, and differences were consid-
ered significant at P<0.05. All statistical analyses were
performed using the SPSS software, version 19 (SPSS,
Inc., Chicago, IL, USA).
Results
Baseline characteristics
Table 1 lists the baseline characteristics of the study
population. Compared with PD patients, both HD-TCC
and HD-AVF patients were more likely to be older
(p<0.001, Table 1) and to have a higher frequency ofdiabetes mellitus (p= 0.017, Table 1), coronary heart dis-
ease (p= 0.007, Table 1) and congestive heart failure
(p= 0.023, Table 1). Both HD-AVF and PD groups
initiated dialysis with similar levels of serum hemoglobin
and serum albumin. In addition, ~80% of both HD-AVF
and PD groups were referred to a nephrologist early.
HD-TCC patients were more likely to be referred to a
nephrologist late (p<0.001, Table 1), and to initiate dialy-
sis with lower hemoglobin (p<0.001, Table 1) and serum
albumin (p<0.001, Table 1). HD-AVF patients were more
likely to initiate RRT with higher estimated glomerular
filtration rate (eGFR) than either HD-TCC or PD
patients (p<0.001, Table 1).
Patient outcomes
Table 2 lists the mean numbers of clinical events of the
study population.
HD-TCC patients were more likely to have higher
numbers of dialysis access-related complications than
HD-AVF and PD patients (p<0.001, Table 2). In par-
ticular, the PD group had the lowest number of mech-
anical access-related complications (p<0.001, Table 2)
and the HD-AVF group the lowest infection rate
(p<0.001, Table 2). Despite the similar number of
infection-free patients in the PD and HD-TCC groups
at 1 year of follow-up, both catheter-related bacteremia
and hospital admissions were significantly higher in
the HD-TCC group (p= 0.004 and 0.034, respectively;
Table 2).
Overall, HD-TCC patients were more likely to have
clinical visits (p= 0.069, Table 2), emergency room visits
(p<0.001, Table 2) and hospital admissions (p<0.001,
Table 2). The mean numbers of hospital days for HD-
AVF, HD-TCC and PD patients were 5.5 ± 13.7,
36.6 ± 40.7 and 5.1 ± 15.1 days, per patient-year at risk,
respectively (p<0.001).
Sixteen patients died during follow-up (HD-AVF,
n = 2; HD-TCC, n = 13; PD, n = 1). The main causes of
death for HD-TCC patients were catheter-related
bacteremia (n = 7), cardiac disease (n = 4), pneumonia
(n = 1) and cancer (n = 1); for HD-AVF patients was
cancer (n = 2) and for PD patients was pyonephrosis
(n = 1). The survival rates at one year were 86.3% and
97.6% for HD and PD patients, respectively (p= 0.044,
log rank test). When stratified for HD vascular access
type, the survival rates at one year were 96.6%, 74.5%
and 97.6% for HD-AVF, HD-TCC and PD groups, re-
spectively (Figure 1; p<0.001, log rank test). Older age
(p= 0.002), diabetes (p= 0.006), cardiovascular disease
(p= 0.026), late referral (p= 0.001) hypoalbuminemia
(p =0.001) and anemia (p =0.002) were all associated
with poorer survival by log rank analysis. The impact
of HD vascular access at the time of dialysis initiation
on survival was considered in more detail in a
Table 1 Baseline characteristics of enrolled patients treated with different dialysis modalities and vascular accesses
(HD-AVF, hemodialysis with arteriovenous fistula; HD-TCC, hemodialysis with catheter; PD, peritoneal dialysis)
Variable HD-AVF (n= 59) HD-TCC (n = 51) PD (n = 42) P
Male sex (%) 60% 55% 52% 0.856
Mean age (y) 62.8 ± 14.3 66.1 ± 15.4 55.1 ± 16.1 0.001
18-44 years 5 (9%) 4 (8%) 9 (21%) 0.047
45-64 years 19 (32%) 12 (24%) 20 (47%) 0.015
65+ years 35 (59%) 35 (69%) 13 (31%) 0.001
Etiology of kidney disease (%)
Diabetes 26 (44%) 22 (42%) 8 (19%) 0.017
Hypertension 7 (12%) 4 (8%) 2 (5%) 0.471
Glomerulonephritis 7 (12%) 3 (6%) 13 (31%) 0.003
Tubulointersticial kidney disease 8 (14%) 10 (20%) 7 (17%) 0.702
Unknown 11 (18%) 12 (24%) 12 (29%) 0.510
Mean Charlson Comorbidity Index 5.1 ± 3.1 5.0 ± 2.5 4.4 ± 2.2 0.574
Low risk (≤ 3) 25 (42%) 17 (34%) 15 (36%) 0.745
Medium risk (4–5) 13 (22%) 11 (21%) 14 (33%) 0.133
High risk (≥6) 21 (36%) 23 (45%) 13 (31%) 0.575
Comorbid conditions (%)
Coronary heart disease 26 (44%) 17 (33%) 6 (14%) 0.007
Congestive heart failure 25 (42%) 18 (35%) 7 (17%) 0.023
Peripheral vascular disease 14 (24%) 11 (22%) 9 (19%) 0.104
Previous stroke 7 (12%) 8 (16%) 2 (5%) 0.095
Diabetes 26 (44%) 23 (45%) 8 (19%) 0.015
Malignant disease 10 (20%) 10 (23%) 11 (26%) 0.432
Late referral (%) 13 (22%) 44 (86%) 9 (21%) <0.001
Time from referral to dialysis initiation,
months (mean± SD)
39 ± 35 11 ± 30 34 ± 28 <0.001
Hemoglobin (g/L) 104 (101, 108) 90 (85, 94) 105 (108, 115) <0.001
eGFR (ml/min per 1.73 m2)* 10.0 (9.2, 10.9) 7.8 (6.8, 8.9) 8.3 (7.7, 9.0) <0.001
Serum creatinine (mg/dL) 5.7 (5.3, 6.1) 8.0 (7.0, 9.1) 6.7 (6.0, 7.4) <0.001
Serum urea (mg/dL) 218 (203, 231) 217 (194, 239) 197 (184, 210) 0.214
Serum albumin (g/L) 37 (35, 38) 33 (31, 34) 39 (38, 40) <0.001
* eGFR, estimated glomerular filtration rate.
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ables. The results of the Cox model are given in
Table 3- HD-TCC use at the time of dialysis initiation
was independently associated with death (HR 16.128,
95%CI [1.431-181.778], p= 0.024).
At the end of follow-up, 97% (n = 57) and 47% (n = 18)
of HD-AVF and HD-TCC patients had a functional fis-
tula as permanent vascular access, respectively. Three
patients switched definitely from PD to HD due to PD-
related peritonitis (n = 2) and tuberculous peritonitis
(n = 1). Only 2 patients received a transplant during the
study period.
Discussion
The study presented here shows that incident HD-TCC
patients experienced a significantly higher mortality rateat one year of dialysis, in comparison with HD-AVF and
PD patients. Infection was the most common cause of
death, whereas the second most common cause was
death related to cardiovascular disease. Dialysis access-
related complications were responsible for 43% (n = 7)
of all deaths, and infection was the single cause respon-
sible for such deaths. Death caused by dialysis access
complications occurred only in the HD-TCC group.
Importantly, HD-TCC patients had approximately twice
as many clinical events related to dialysis access than ei-
ther HD-AVF or PD patients (mainly access-related
bacteremia episodes and hospitalizations). In contrast,
most of the vascular and peritoneal dialysis access com-
plications in the HD-AVF and PD groups were not ser-
ious clinical events, and no dialysis access-related deaths
occurred in either these two groups. Although HD-TCC
Table 2 Dialysis access-related and overall clinical events of enrolled patients treated with different dialysis modalities
and vascular accesses (HD-AVF, hemodialysis with arteriovenous fistula; HD-TCC, hemodialysis with catheter; PD,
peritoneal dialysis), per patient-year at risk (mean±SD)
Clinical events HD-AVF HD-TCC PD P
(n = 59) (n =51) (n = 42)
Dialysis access-related
Mechanical complications 0.93 ± 1.40 0.82 ± 1.49 0.07 ± 0.26 <0.001
Fistula related 0.73 ± 0.99 0.29 ± 0.64 0 <0.001
Catheter related 0.20 ± 0.71 0.53 ± 1.12 0.07 ± 0.26 0.114
Infectious complications
Patients infection free, at year 1, N (%) 59 (100%) 33 (65%) 24 (57%) <0.001
Peritonitis 0 0 0.57 ± 0.74 0.002
Bacteremia 0 0.71 ± 1.29 0 0.004
Total 0.93 ± 1.40 1.53 ± 1.89 0.64 ± 0.83 <0.001
Overall
Dialysis access-related complications * 0.93 ± 1.40 1.53 ± 1.89 0.64 ± 0.83 <0.001
Clinical visits 4.17 ± 4.29 6.35 ± 10.25 3.38 ± 3.41 0.069
Emergency room visits 1.42 ± 2.38 3.06 ± 3.23 1.62 ± 1.75 <0.001
Hospital admissions 0.66 ± 1.14 2.04 ± 1.55 0.50 ± 0.74 <0.001
Dialysis accesss-related 0.07 ± 0.25 0.47 ± 1.09 0.14 ± 0.42 0.034
Other 0.59 ± 1.03 1.57 ± 1.05 0.36 ± 0.62 0.010
Total 7.18 ± 6.76 12.98 ± 12.61 6.14 ± 4.12 <0.001
* Includes all dialysis access-related mechanical and infectious complications.
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patients, HD-TCC patients were referred to the neph-
rologist later, which might explain the delay in AVF cre-
ation in this group. In contrast, both incident HD-AVF
and PD patients were referred to the nephrologist early
and could thus benefit from appropriate vascular and
peritoneal access placement in due time. Despite differ-
ent baseline characteristics, both the HD-AVF and PD
groups had similarly high survival rates at year 1.Figure 1 Kaplan-Meier plots of survival in incident dialysis patients w
on survival. Survival curves for HD-AVF (hemodialysis with arteriovenous fi
dashed line), and PD (peritoneal dialysis, solid line) demonstrate higher 1-yMultivariate analysis showed that HD-TCC use at the
time of dialysis initiation was the important factor asso-
ciated with poor prognosis. Taken together, our results
strongly suggest that HD vascular access type at the time
of dialysis initiation might explain the differences in out-
come observed between the incident HD and PD popula-
tions. Our results corroborate the recent findings of
Perl et al., [15] in incident adult dialysis patients on the
Canadian Organ Replacement Register who found thatith log rank analysis to assess the significance of dialysis access
stula, dotted line), HD-TCC (hmodialysis with tunneled cuffed catheter,
ear mortality in HD-TCC patients.
Table 3 Results of the Cox multivariate analysis for the
relationship between co-morbid factors, dialysis access at
dialysis initiation and death in incident dialysis patients
(HD-AVF, hemodialysis arteriovenous fistula; HD-TCC,








Age (per year) 1.080 0.996-1.171 0.062
Diabetes 0.487 0.139-2.288 0.318
Coronary heart disease 1.875 0.381-9.227 0.439
Congestive heart failure 0.497 0.117-2.158 0.497
Peripheral vascular disease 0.499 0.114-2.190 0.357
Previous stroke 0.197 0.032-1.225 0.081
Late referral 1.009 0.990-1.028 0.378
Albumin 0.917 0.814-1.033 0.153
Hemoglobin 0.999 0.948-1.054 0.975
eGFR* 1.135 0.903-1.426 0.279
Dialysis access
PD (reference)
HD-AVF 0.734 0.056-9.656 0.814
HD-TCC 16.128 1.431-181.778 0.024
* eGFR, estimated glomerular filtration rate.
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of death compared to both HD-AVF and PD patients.
Our findings are also in agreement with the recent
report of Quinn et al., [21] that showed no difference in
survival between PD and HD patients who received
> 4 months of predialysis care. Also, Raithatha et al. [16]
recently showed that the use of HD-catheter is one of
the key features of late referral that determines poor
prognosis. In the present study, ~80% of both HD-AVF
and PD patients were referred to the nephologist early
and experienced similarly high survival rates in the first
year of dialysis, compared to HD-TCC patients. Our
results support the need for early referral of ESRD
patients to nephrology centers to provide the opportun-
ity for patient selection of RRT modality and timely cre-
ation of the appropriate dialysis access [22].
Most reports that have used USRDS data do not in-
clude the critical initial 90-day period on dialysis. This is
a time period when a high proportion of HD patients
are using catheters as bridging access devices [12]. In
the present study, survival rates of HD-TCC, HD-AVF
and PD groups at 90 days of follow-up were 88%, 100%
and 100%, respectively. Exclusion of this period in the
analysis would probably underestimate the morbidity
and mortality rates of the HD-TCC group.
One interesting finding of the present study was that
bacteremia only occurred in HD-TCC patients, refuting
the common misconception that PD is associated withan overall higher rate of severe infection than HD. In
addition, PD patients had the lowest number of mechan-
ical access-related complications. Our results support
the previous findings of Oliver et al. [23,24] and Povlsen
et al. [2,25,26] by showing that patients who choose PD
require fewer access interventions and do not face an
increased risk of access-related complications compared
to HD patients.
As a retrospective study, this study has the limitations
of such an approach. As with all observational studies,
there may have been selection bias, in particular influ-
enced by patient treatment preferences and time of re-
ferral to the nephrologist. PD patients were younger and
had lower comorbid illness, compared to HD patients.
The patient population consisted mainly of Caucasian
Europeans, which makes it impossible to draw conclu-
sions for other ethnic groups. Peritoneal dialysis patients
were treated in a single academic nephrology centre,
whereas HD patients were treated in separate peripheral
renal centers, although this is a reflection of the local
distribution of patients between modalities.Conclusion
Our study provides evidence favoring the view that HD
vascular access type at renal replacement therapy initi-
ation is an important modifier of the relationship be-
tween dialysis modality and survival among incident
dialysis patients. Our results emphasize the need for an
early referral program for ESRD patients so that those
who choose HD have a functioning AVF, and those who
choose PD have a Tenckhoff catheter placed in due time.
We believe such a policy would decrease the risk of dia-
lysis morbidity/mortality.
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